Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era.
作者信息
Wang Stephen Y, Juthani Prerak V, Borges Kelly A, Shallow Marcus K, Gupta Akash, Price Christina, Won Christine H, Chun Hyung J
机构信息
Department of Internal Medicine, New Haven, CT 06511, USA.
Yale School of Medicine, New Haven, CT 06511, USA.
出版信息
Lancet Microbe. 2022 Jan;3(1):e4-e5. doi: 10.1016/S2666-5247(21)00306-2. Epub 2021 Dec 3.
Abstract
摘要
相似文献
1
Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔（B.1.617.2）变异株时代的严重突破性新冠病毒病病例
Lancet Microbe. 2022 Jan;3(1):e4-e5. doi: 10.1016/S2666-5247(21)00306-2. Epub 2021 Dec 3.
2
An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward.一起德尔塔变异株引起的精神科封闭病房突破性感染事件
J Korean Med Sci. 2022 Jan 24;37(4):e28. doi: 10.3346/jkms.2022.37.e28.
3
Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy.意大利伦巴第地区出现 E484K 变异株 SARS-CoV-2 突破性感染。
Emerg Infect Dis. 2021 Dec;27(12):3180-3182. doi: 10.3201/eid2712.211792. Epub 2021 Sep 9.
4
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
5
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间，加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局，期间 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
6
SARS-CoV-2 Sequence Analysis during COVID-19 Case Surge, Liberia, 2021.2021 年利比里亚 COVID-19 病例激增期间的 SARS-CoV-2 序列分析。
Emerg Infect Dis. 2021 Dec;27(12):3185-3188. doi: 10.3201/eid2712.211818. Epub 2021 Oct 28.
7
SARS-CoV-2 Delta Variant among Asiatic Lions, India.印度亚洲狮中的新冠病毒德尔塔变异株
Emerg Infect Dis. 2021 Oct;27(10):2723-2725. doi: 10.3201/eid2710.211500.
8
Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2.SARS-CoV-2 Delta变异株（B.1.617.2）快速抗原检测的比较敏感性
Viruses. 2021 Oct 29;13(11):2183. doi: 10.3390/v13112183.
9
Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021.2021年5月，印度，新冠疫苗接种者与未接种者中德尔塔变异株的优势情况
J Infect. 2022 Jan;84(1):94-118. doi: 10.1016/j.jinf.2021.08.006. Epub 2021 Aug 6.
10
Large-scale synchronized replacement of Alpha (B.1.1.7) variant by the Delta (B.1.617.2) variant of SARS-COV-2 in the COVID-19 pandemic.在 COVID-19 大流行期间，大规模同步替换 SARS-COV-2 的 Alpha（B.1.1.7）变体为 Delta（B.1.617.2）变体。
Math Biosci Eng. 2022 Feb 7;19(4):3591-3596. doi: 10.3934/mbe.2022165.
引用本文的文献
1
Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece.2022年至2023年希腊SARS-CoV-2奥密克戎BA.2和BA.5疫情期间，加强疫苗剂量对新冠肺炎住院患者的保护作用。
Infect Med (Beijing). 2024 Oct 18;3(4):100144. doi: 10.1016/j.imj.2024.100144. eCollection 2024 Dec.
2
Impact of phased COVID-19 vaccine rollout on anxiety and depression among US adult population, January 2019-February 2023: a population-based interrupted time series analysis.2019年1月至2023年2月期间，新冠疫苗分阶段推出对美国成年人群焦虑和抑郁的影响：一项基于人群的中断时间序列分析。
Lancet Reg Health Am. 2024 Aug 9;37:100852. doi: 10.1016/j.lana.2024.100852. eCollection 2024 Sep.
3
COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal.尼泊尔 BPKIHS 接种疫苗人群中的 COVID-19 突破性感染。
BMC Infect Dis. 2024 Sep 19;24(1):1003. doi: 10.1186/s12879-024-09902-z.
4
SARS-COV-2 breakthrough infection and its covariates among healthcare providers of a hospital in Bangladesh during the omicron wave.孟加拉国一家医院的医护人员在奥密克戎毒株流行期间的新冠病毒突破性感染及其相关因素。
Heliyon. 2024 Sep 2;10(17):e37287. doi: 10.1016/j.heliyon.2024.e37287. eCollection 2024 Sep 15.
5
Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin.接种疫苗会损害针对奥密克戎突破性感染的新免疫反应，这是原始抗原性错误的前提条件。
Nat Commun. 2024 Apr 10;15(1):3102. doi: 10.1038/s41467-024-47451-w.
6
Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure.对SARS-CoV-2特异性长期适应性免疫反应的评估：各种疫苗接种和奥密克戎暴露的影响
Vaccines (Basel). 2024 Mar 13;12(3):301. doi: 10.3390/vaccines12030301.
7
The Moderating Role of Anxiety and Depressive Symptoms in Protective Effects of Health Behaviors among Clients Using Mental Health Services.焦虑和抑郁症状在心理健康服务使用者健康行为保护作用中的调节作用
J Clin Med. 2024 Mar 18;13(6):1753. doi: 10.3390/jcm13061753.
8
Epidemiology, clinical features and outcomes of hospitalized patients with COVID-19 by vaccination status: a multicenter historical cohort study.接种疫苗状况对 COVID-19 住院患者的流行病学、临床特征和结局的影响：一项多中心历史队列研究。
Virol J. 2024 Mar 21;21(1):71. doi: 10.1186/s12985-024-02325-x.
9
The descriptive epidemiology of pre-omicron SARS-CoV-2 breakthrough infections and severe outcomes in Manitoba, Canada.加拿大曼尼托巴省新冠病毒奥密克戎变异株出现之前的突破性感染及严重后果的描述性流行病学研究
Front Epidemiol. 2024 Jan 12;3:1248847. doi: 10.3389/fepid.2023.1248847. eCollection 2023.
10
A chronological review of COVID-19 case fatality rate and its secular trend and investigation of all-cause mortality and hospitalization during the Delta and Omicron waves in the United States: a retrospective cohort study.对 COVID-19 病死率及其季节性趋势的时间序列回顾，以及对美国 Delta 和奥密克戎浪潮期间全因死亡率和住院治疗的调查：一项回顾性队列研究。
Front Public Health. 2023 Sep 15;11:1143650. doi: 10.3389/fpubh.2023.1143650. eCollection 2023.
本文引用的文献
1
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性：一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
2
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.卡塔尔：BNT162b2 疫苗对 SARS-CoV-2 感染的保护作用逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e83. doi: 10.1056/NEJMoa2114114. Epub 2021 Oct 6.
3
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.辉瑞-BioNTech 新冠疫苗接种 6 个月后免疫体液反应逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
4
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.辉瑞-BioNTech 疫苗加强针在以色列预防新冠病毒。
N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15.
5
Hospitalisation among vaccine breakthrough COVID-19 infections.疫苗突破性新冠病毒感染导致的住院情况。
Lancet Infect Dis. 2021 Nov;21(11):1485-1486. doi: 10.1016/S1473-3099(21)00558-2. Epub 2021 Sep 7.
6
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
7
COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.美国疾病预防控制中心报告的 2021 年 1 月 1 日至 4 月 30 日 COVID-19 疫苗突破性感染病例。
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793. doi: 10.15585/mmwr.mm7021e3.
Zotero 插件